MINISTRY OF HEALTH CLINICAL PRACTICE GUIDELINES: SCHIZOPHRENIA
Singapore Med J 2011; 52(7): 521-526

The correct print version on page 524 is as follows:

**GPP** For all patients on clozapine, clinicians should have their full blood count monitored weekly for the first 18 weeks and monthly thereafter (pg 16).

**D** Electroconvulsive therapy should be considered for patients who have not responded to an adequate trial of antipsychotics and for patients with life-threatening symptoms such as catatonia and prominent depressive symptoms (pg 16).

*Grade D, Level 3*

**A** Electroconvulsive therapy should not be prescribed as first-line treatment or monotherapy in schizophrenia (pg 17).

*Grade A, Level 1+

**Adjunctive medications**

**A** Antidepressants should be considered when depressive symptoms emerge during the stable phase of schizophrenia (post-psychotic depression) (pg 18).

*Grade A, Level 1+

**D** Antidepressants should be used at the same dose as for treatment of major depressive disorder (pg 18).

*Grade D, Level 4*

**A** Anticholinergic agents have been shown to be effective in reducing the severity of antipsychotic-induced extrapyramidal side effects and may be prescribed to patients experiencing these side effects (pg 19).

*Grade A, Level 1+

**Editor’s note:** The corrected version is available online at: http://smj.sma.org.sg/5207/5207pg1.pdf